Conversely, while HDAC6 inhibition effectively suppresses GBM cell viability, it paradoxically upregulates KYNU, C3AR1, and C5AR1, potentially undermining its therapeutic efficacy. This evidence concerns the gene HDAC6 and glioblastoma.